

“DiagnosTear has initiated its clinical trial to evaluate source and progress of Dry Eye Disease”

Diagnostear, a subsidiary of BioLight, is proud to announce the recruitment in India of the first participant for its clinical trial of diagnosing Dry Eye Disease (DES)

The trial is expected to include approximately 500 patients and 100 healthy volunteers and is part of a commercial collaboration agreement between Diagnostear, together with LV Prasad Eye Institute (**LVPEI**), a leading ophthalmic medical center in India and a global pharmaceutical company

Diagnostear, of which 82% is owned by BioLight is engaged in the development of TeaRx® technology that is designed to diagnose various diseases of the front of the eye by a multi parameter objective examination of the composition of the tear fluid.

DiagnosTear has already proven its technology to diagnose DES in 4 clinical studies in US and Israel and gained CE approval for its diagnostic kits.

The main objectives of the current clinical trial are to examine Diagnostear’s capabilities in the diagnosis of patients suffering from DES, while identifying the various characterizations and background of DES for a more accurate, focused and efficient treatment.

The clinical trial is led by Dr. Sayan Basu, who also serves as Director of Research at the Prof. Brien Holden Eye Research Centre, L V Prasad Eye Institute (LVPEI) and as a network Director across LVPEI's various centers of ophthalmology. Dr. Basu is one of the most prominent researchers in the field of innovative treatments for the cornea of the eye, and his specialization includes treatment of dry eye disease and visual impairment.

Dr. Sayan Basu stated: “We are pleased to collaborate with Diagnostear, which developed its TeaRx Product that enables immediate assistance to many patients, by properly diagnosing and tailoring the treatment. Accurate and rapid diagnosis of dry eye syndrome and adjusting the treatment according to such diagnostics, provides us, the ophthalmologists, with an especially important tool that can prevent the deterioration of the disease and accurately and significantly shorten the duration and the efficiency of treatment of patients.”

Diagnostear Chairman and CEO of BioLight, Yaacov Michlin, added: “Diagnostear's product has a unique platform for detecting various eye diseases and the LVPEI comprehensive trial of dry eye disease is an important milestone in this process.

We hope that the experiment led by Dr. Basu will progress well towards achieving the ambitious goal of recruiting 600 patients who will be tested up to 4 times within a period of 6 months. This experiment is expected to produce extensive information on the development of dry eye disease in a way that to the best of our knowledge, is unprecedented”.